Login to Your Account

Transparency, Fairness Needed for the Biosimilar Playing Field

By Mari Serebrov
Washington Editor

Wednesday, June 19, 2013
The longer timelines the FDA is proposing for biosimilar meetings and reviews add insult to the injury of expecting sponsors of the follow-on biologics (FOBs) to pay user fees up front, according to several generic drugmakers.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription